Hester Biosciences Limited

NSEI:HESTERBIO Stock Report

Market Cap: ₹20.3b

Hester Biosciences Balance Sheet Health

Financial Health criteria checks 3/6

Hester Biosciences has a total shareholder equity of ₹3.1B and total debt of ₹2.4B, which brings its debt-to-equity ratio to 76.1%. Its total assets and total liabilities are ₹6.7B and ₹3.6B respectively. Hester Biosciences's EBIT is ₹512.7M making its interest coverage ratio 6.9. It has cash and short-term investments of ₹167.9M.

Key information

76.1%

Debt to equity ratio

₹2.39b

Debt

Interest coverage ratio6.9x
Cash₹167.88m
Equity₹3.14b
Total liabilities₹3.55b
Total assets₹6.69b

Recent financial health updates

These 4 Measures Indicate That Hester Biosciences (NSE:HESTERBIO) Is Using Debt Extensively

Nov 25
These 4 Measures Indicate That Hester Biosciences (NSE:HESTERBIO) Is Using Debt Extensively

These 4 Measures Indicate That Hester Biosciences (NSE:HESTERBIO) Is Using Debt Extensively

Aug 25
These 4 Measures Indicate That Hester Biosciences (NSE:HESTERBIO) Is Using Debt Extensively

Recent updates

Hester Biosciences Limited's (NSE:HESTERBIO) CEO Compensation Looks Acceptable To Us And Here's Why

Aug 23
Hester Biosciences Limited's (NSE:HESTERBIO) CEO Compensation Looks Acceptable To Us And Here's Why

What Hester Biosciences Limited's (NSE:HESTERBIO) 26% Share Price Gain Is Not Telling You

Jul 27
What Hester Biosciences Limited's (NSE:HESTERBIO) 26% Share Price Gain Is Not Telling You

Revenues Working Against Hester Biosciences Limited's (NSE:HESTERBIO) Share Price

Jun 12
Revenues Working Against Hester Biosciences Limited's (NSE:HESTERBIO) Share Price

Hester Biosciences (NSE:HESTERBIO) Has Announced A Dividend Of ₹10.00

Aug 01
Hester Biosciences (NSE:HESTERBIO) Has Announced A Dividend Of ₹10.00

Would Hester Biosciences Limited (NSE:HESTERBIO) Be Valuable To Income Investors?

Mar 03
Would Hester Biosciences Limited (NSE:HESTERBIO) Be Valuable To Income Investors?

Did You Miss Hester Biosciences' (NSE:HESTERBIO) Whopping 308% Share Price Gain?

Feb 13
Did You Miss Hester Biosciences' (NSE:HESTERBIO) Whopping 308% Share Price Gain?

What Is The Ownership Structure Like For Hester Biosciences Limited (NSE:HESTERBIO)?

Jan 26
What Is The Ownership Structure Like For Hester Biosciences Limited (NSE:HESTERBIO)?

Who Has Been Buying Hester Biosciences Limited (NSE:HESTERBIO) Shares?

Jan 11
Who Has Been Buying Hester Biosciences Limited (NSE:HESTERBIO) Shares?

Hester Biosciences Limited's (NSE:HESTERBIO) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Dec 25
Hester Biosciences Limited's (NSE:HESTERBIO) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Are Hester Biosciences's (NSE:HESTERBIO) Statutory Earnings A Good Guide To Its Underlying Profitability?

Dec 10
Are Hester Biosciences's (NSE:HESTERBIO) Statutory Earnings A Good Guide To Its Underlying Profitability?

These 4 Measures Indicate That Hester Biosciences (NSE:HESTERBIO) Is Using Debt Extensively

Nov 25
These 4 Measures Indicate That Hester Biosciences (NSE:HESTERBIO) Is Using Debt Extensively

How Does Hester Biosciences Limited (NSE:HESTERBIO) Fare As A Dividend Stock?

Nov 10
How Does Hester Biosciences Limited (NSE:HESTERBIO) Fare As A Dividend Stock?

If You Had Bought Hester Biosciences (NSE:HESTERBIO) Shares Five Years Ago You'd Have Earned 212% Returns

Oct 26
If You Had Bought Hester Biosciences (NSE:HESTERBIO) Shares Five Years Ago You'd Have Earned 212% Returns

What Type Of Shareholders Own The Most Number of Hester Biosciences Limited (NSE:HESTERBIO) Shares?

Oct 05
What Type Of Shareholders Own The Most Number of Hester Biosciences Limited (NSE:HESTERBIO) Shares?

Are Strong Financial Prospects The Force That Is Driving The Momentum In Hester Biosciences Limited's NSE:HESTERBIO) Stock?

Sep 14
Are Strong Financial Prospects The Force That Is Driving The Momentum In Hester Biosciences Limited's NSE:HESTERBIO) Stock?

These 4 Measures Indicate That Hester Biosciences (NSE:HESTERBIO) Is Using Debt Extensively

Aug 25
These 4 Measures Indicate That Hester Biosciences (NSE:HESTERBIO) Is Using Debt Extensively

How Much Are Hester Biosciences Limited (NSE:HESTERBIO) Insiders Taking Off The Table?

Aug 07
How Much Are Hester Biosciences Limited (NSE:HESTERBIO) Insiders Taking Off The Table?

Hester Biosciences Limited (NSE:HESTERBIO) Is Yielding 0.5% - But Is It A Buy?

Jul 07
Hester Biosciences Limited (NSE:HESTERBIO) Is Yielding 0.5% - But Is It A Buy?

Financial Position Analysis

Short Term Liabilities: HESTERBIO's short term assets (₹2.2B) exceed its short term liabilities (₹1.3B).

Long Term Liabilities: HESTERBIO's short term assets (₹2.2B) do not cover its long term liabilities (₹2.3B).

Debt to Equity History and Analysis

Debt Level: HESTERBIO's net debt to equity ratio (70.7%) is considered high.

Reducing Debt: HESTERBIO's debt to equity ratio has increased from 56.6% to 76.1% over the past 5 years.

Debt Coverage: HESTERBIO's debt is well covered by operating cash flow (27.9%).

Interest Coverage: HESTERBIO's interest payments on its debt are well covered by EBIT (6.9x coverage).

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 17:32
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hester Biosciences Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vaishali Kumar ParkarBOB Capital Markets Ltd.
Kameswari V. S. ChavaliFirstCall Research
Siddhant KhandekarICICIdirect.com